{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:53:58Z","timestamp":1786996438902,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.rxeng.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T07:25:14Z","timestamp":1729495514000},"page":"S75-S88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S2","title":["Hepatobiliary contrast agents for Liver Magnetic Resonance Imaging"],"prefix":"10.1016","volume":"66","author":[{"given":"A.","family":"Perez-Girbes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mart\u00ed-Bonmat\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rxeng.2024.05.002_bib0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1102\/1470-7330.2012.9022","article-title":"Liver-specific contrast agents","volume":"12","author":"Koh","year":"2012","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0010","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1007\/s00330-003-1912-x","article-title":"Currently used non-specific extracellular MR contrast media","volume":"13","author":"Bellin","year":"2003","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1148\/radiol.2020202903","article-title":"Use of intravenous gadolinium-based contrast media in patients with kidney disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation","volume":"298","author":"Weinreb","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00261-017-1325-y","article-title":"LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound","volume":"43","author":"Kambadakone","year":"2018","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0025","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s00330-024-10606-w","article-title":"ESR Essentials: diagnosis of hepatocellular carcinoma-practice recommendations by ESGAR","volume":"34","author":"Cannella","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jhep.2012.01.031","article-title":"Primovist, Eovist: what to expect?","volume":"57","author":"Van Beers","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0035","first-page":"153","article-title":"Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1","volume":"290","author":"van Montfoort","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0040","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s13318-016-0382-x","article-title":"Liver perfusion modifies Gd-DTPA and Gd-BOPTA hepatocyte concentrations through transfer clearances across sinusoidal membranes","volume":"42","author":"Daire","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0045","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jmri.23725","article-title":"MRI con-trast agents: basic chemistry and safety","volume":"36","author":"Hao","year":"2012","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0050","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1007\/s00330-019-06113-y","article-title":"Lesion detection performance of an abbreviated gadoxetic acid-enhanced MRI protocol for colorectal liver metastasis surveillance","volume":"29","author":"Canellas","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00261-017-1228-y","article-title":"LI-RADS\u00ae algorithm: CT and MRI","volume":"43","author":"Chernyak","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0060","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00330-015-3900-3","article-title":"ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents","volume":"26","author":"Neri","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/RLI.0000000000000806","article-title":"Transient severe motion artifact on arterial phase in gadoxetic acid-enhanced liver magnetic resonance imaging: a systematic review and meta-analysis","volume":"57","author":"Kim","year":"2022","journal-title":"Invest Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0070","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1007\/s00330-022-08885-2","article-title":"Transient severe motion artifacts on gadoxetic acid-enhanced MRI: risk factor analysis in 2230 patients","volume":"32","author":"Jang","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0075","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1007\/s00330-020-07637-4","article-title":"Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging","volume":"31","author":"Koh","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0080","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3350\/cmh.2022.0294","article-title":"2022 KLCA-NCC Korea practice guidelines for the mana-gement of hepatocellular carcinoma","volume":"28","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.rcl.2022.04.005","article-title":"Update on MR contrast agents for liver imaging: what to use and when","volume":"60","author":"Kalor","year":"2022","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0090","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190989","article-title":"Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI","volume":"93","author":"Hui","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0095","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1007\/s00261-020-02779-x","article-title":"Quantification of liver function using gadoxetic acid-enhanced MRI","volume":"45","author":"Poetter-Lang","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0100","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/RLI.0000000000000286","article-title":"Assessment of orthotopic liver transplant graft survival on gadoxetic acid-enhanced magnetic resonance imaging using qualitative and quantitative parameters","volume":"51","author":"Bastati","year":"2016","journal-title":"Invest Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0105","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1053\/j.gastro.2016.11.042","article-title":"Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation","volume":"152","author":"Nault","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0110","doi-asserted-by":"crossref","DOI":"10.1148\/rg.220134","article-title":"Hepatocellular adenomas: molecular basis and multimodality imaging update","volume":"43","author":"Tse","year":"2023","journal-title":"Radiographics"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1148\/radiol.2015142986","article-title":"Focal nodular hyperplasia and hepatocellular adenoma: accuracy of gadoxetic acid-enhanced MR imaging\u2014a systematic review","volume":"277","author":"McInnes","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1148\/radiol.2015142366","article-title":"Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging","volume":"277","author":"Ba-Ssalamah","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2214\/AJR.22.27989","article-title":"Hepatic adenoma subtypes on hepatobiliary phase of gadoxetic acid-enhanced MRI: systematic review and meta-analysis","volume":"220","author":"Kim","year":"2023","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0130","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1148\/rg.210156","article-title":"Focal nodular hyperplasia and focal nodular hyperplasia-like lesions","volume":"42","author":"LeGout","year":"2022","journal-title":"Radiographics"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0135","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2214\/AJR.17.18867","article-title":"Focal nodular hyperplasia after treatment with oxaliplatin: a multiinstitutional series of cases diagnosed at MRI","volume":"210","author":"Furlan","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0140","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s00261-017-1181-9","article-title":"Benign nodules in post-Fontan livers can show imaging features considered diagnostic for hepatocellular carcinoma","volume":"42","author":"Wells","year":"2017","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0145","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00261-019-02119-8","article-title":"CT and MR imaging findings of the livers in adults with Fontan palliation: an observational study","volume":"45","author":"Yang","year":"2020","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1148\/radiology.210.2.r99fe13443","article-title":"Hepatic nodules in Budd-Chiari syndrome: imaging features","volume":"210","author":"Vilgrain","year":"1999","journal-title":"Radiology"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0155","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0160","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hepr.13892","article-title":"Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)","volume":"53","author":"Hasegawa","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0165","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1002\/cncr.30237","article-title":"Comparison of hepatocellular carcinoma in Eastern versus Western populations","volume":"122","author":"Choo","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0170","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3350\/cmh.2018.0090","article-title":"Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0175","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1007\/s00330-011-2165-8","article-title":"The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging","volume":"21","author":"Kitao","year":"2011","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13244-020-00928-w","article-title":"Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting","volume":"12","author":"Vernuccio","year":"2021","journal-title":"Insights Imaging"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0185","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1016\/j.ejrad.2012.07.021","article-title":"Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features","volume":"81","author":"Kim","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0190","doi-asserted-by":"crossref","first-page":"100","DOI":"10.14218\/JCTH.2023.00130","article-title":"Liver lesions at risk of transformation into hepatocellular carcinoma in cirrhotic patients: hepatobiliary phase hypointense nodules without arterial phase hyperenhancement","volume":"12","author":"Brandi","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0195","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1148\/radiol.2020192275","article-title":"Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced mri: a multicenter study","volume":"296","author":"Joo","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0200","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/RCT.0b013e3182706562","article-title":"Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid\u2013enhanced magnetic resonance imaging","volume":"36","author":"Kim","year":"2012","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0205","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.1840220341","article-title":"Terminology of nodular hepatocellular lesions","volume":"22","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0210","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1007\/s00330-019-06329-y","article-title":"Doughnut-like hyperintense nodules on hepatobiliary phase without arterial-phase hyperenhancement in cirrhotic liver: imaging and clinicopathological features","volume":"29","author":"Kozaka","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0215","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/j.jacr.2017.01.037","article-title":"ACR Appropriateness Criteria\u00ae Suspected Liver Metastases","volume":"14","author":"Kaur","year":"2017","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0220","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1007\/s00330-016-4250-5","article-title":"A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases","volume":"26","author":"Vilgrain","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0225","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s00330-020-07344-0","article-title":"The diagnostic performance of a simulated \u201cshort\u201d gadoxetic acid-enhanced MRI protocol is similar to that of a conventional protocol for the detection of colorectal liver metastases","volume":"31","author":"Ghorra","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0230","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1007\/s00330-020-06930-6","article-title":"The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor","volume":"30","author":"Hayoz","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0235","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/MPA.0000000000000920","article-title":"Magnetic resonance imaging of neuroendocrine tumor hepatic metastases: does hepatobiliary phase imaging improve lesion conspicuity and interobserver agreement of lesion measurements?","volume":"46","author":"Morse","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0240","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00261-016-0936-z","article-title":"3D T2-weighted and Gd-EOB-DTPA-enhanced 3D T1-weighted MR cholangiography for evaluation of biliary anatomy in living liver donors","volume":"42","author":"Cai","year":"2017","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0245","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.surg.2021.02.018","article-title":"Improved management of grade B biliary leaks after complex liver resections using gadoxetic acid disodium-enhanced magnetic resonance cholangiography","volume":"170","author":"Citterio","year":"2021","journal-title":"Surgery"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0250","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00261-023-04176-6","article-title":"Gd-EOB-DTPA enhanced MRI based radiomics combined with clinical variables in stratifying hepatic functional reserve in HBV infected patients","volume":"49","author":"Hu","year":"2024","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.rxeng.2024.05.002_bib0255","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3348\/kjr.2021.0892","article-title":"Deep learning-based assessment of functional liver capacity using gadoxetic acid-enhanced hepatobiliary phase MRI","volume":"23","author":"Park","year":"2022","journal-title":"Korean J Radiol"}],"container-title":["Radiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173510724001137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173510724001137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T06:59:14Z","timestamp":1732604354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173510724001137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":51,"alternative-id":["S2173510724001137"],"URL":"https:\/\/doi.org\/10.1016\/j.rxeng.2024.05.002","relation":{},"ISSN":["2173-5107"],"issn-type":[{"value":"2173-5107","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatobiliary contrast agents for Liver Magnetic Resonance Imaging","name":"articletitle","label":"Article Title"},{"value":"Radiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rxeng.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rx.2024.05.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SERAM. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}